Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California. Exicure, Inc. was formerly a subsidiary of Exicure Hitron Inc.…
Exicure Announces Filing of Notification of Late Filing on Form 12b-25
Exicure (NASDAQ: XCUR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 0.9001 USD on 20 November 2026, down 78.8% over 52 weeks. Its 52-week range is 0.7782 USD to 9.480 USD: the price is 90.5% below the high and 15.7% above the low.
Its market capitalisation is 5.89M USD.
Exicure reports return on equity of -126.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.72M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.